Literature DB >> 28775066

The interplay between iron and oxygen homeostasis with a particular focus on the heart.

Samira Lakhal-Littleton1, Peter Alistair Robbins2.   

Abstract

Iron is subject to tight homeostatic control in mammals. At the systemic level, iron homeostasis is controlled by the liver-derived hormone hepcidin acting on its target ferroportin in the gut, spleen, and liver, which form the sites of iron uptake, recycling, and storage, respectively. At the cellular level, iron homeostasis is dependent on the iron regulatory proteins IRP1/IRP2. Unique chemical properties of iron underpin its importance in biochemical reactions involving oxygen. As such, it is not surprising that there are reciprocal regulatory links between iron and oxygen homeostasis, operating both at the systemic and cellular levels. Hypoxia activates the IRP pathway, and in addition suppresses liver hepcidin through endocrine factors that have yet to be fully elucidated. This review summarizes current knowledge on the interplay between oxygen and iron homeostasis and describes recent insights gained into this interaction in the context of the heart. These include the recognition that the hepcidin/ferroportin axis plays a vital role in the regulation of intracellular iron homeostasis as well as regulating systemic iron availability. As is the case for other aspects of iron homeostasis, hypoxia significantly modulates the function of the hepcidin/ferroportin pathway in the heart. Key areas still to understand are the interactions between cardiac iron and diseases of the heart where hypoxia is a recognized component.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  ferroportin; heart; hepcidin; iron; oxygen

Mesh:

Substances:

Year:  2017        PMID: 28775066      PMCID: PMC5668453          DOI: 10.1152/japplphysiol.00237.2017

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  62 in total

Review 1.  Chemistry for an essential biological process: the reduction of ferric iron.

Authors:  J L Pierre; M Fontecave; R R Crichton
Journal:  Biometals       Date:  2002-12       Impact factor: 2.949

Review 2.  Regulation of oxygen affinity of hemoglobin: influence of structure of the globin on the heme iron.

Authors:  M F Perutz
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

Review 3.  Biochemical basis for the manifestations of iron deficiency.

Authors:  P R Dallman
Journal:  Annu Rev Nutr       Date:  1986       Impact factor: 11.848

4.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

5.  The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.

Authors:  Adriana Donovan; Christine A Lima; Jack L Pinkus; Geraldine S Pinkus; Leonard I Zon; Sylvie Robine; Nancy C Andrews
Journal:  Cell Metab       Date:  2005-03       Impact factor: 27.287

6.  Serum hepcidin-20 is elevated during the acute phase of myocardial infarction.

Authors:  Hiroshi Suzuki; Ken Toba; Kiminori Kato; Takuya Ozawa; Naohisa Tomosugi; Masato Higuchi; Taro Kusuyama; Yoshitaka Iso; Naohiko Kobayashi; Sin-ichiro Yokoyama; Noboru Fukuda; Hideki Saitoh; Kohei Akazawa; Yoshifusa Aizawa
Journal:  Tohoku J Exp Med       Date:  2009-06       Impact factor: 1.848

7.  Lethal Cardiomyopathy in Mice Lacking Transferrin Receptor in the Heart.

Authors:  Wenjing Xu; Tomasa Barrientos; Lan Mao; Howard A Rockman; Anthony A Sauve; Nancy C Andrews
Journal:  Cell Rep       Date:  2015-10-08       Impact factor: 9.423

8.  An essential cell-autonomous role for hepcidin in cardiac iron homeostasis.

Authors:  Samira Lakhal-Littleton; Magda Wolna; Yu Jin Chung; Helen C Christian; Lisa C Heather; Marcella Brescia; Vicky Ball; Rebeca Diaz; Ana Santos; Daniel Biggs; Kieran Clarke; Benjamin Davies; Peter A Robbins
Journal:  Elife       Date:  2016-11-29       Impact factor: 8.140

9.  Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status.

Authors:  Josep Comín-Colet; Cristina Enjuanes; Gina González; Ainhoa Torrens; Mercè Cladellas; Oona Meroño; Nuria Ribas; Sonia Ruiz; Miquel Gómez; José Maria Verdú; Jordi Bruguera
Journal:  Eur J Heart Fail       Date:  2013-05-22       Impact factor: 15.534

10.  Induced Disruption of the Iron-Regulatory Hormone Hepcidin Inhibits Acute Inflammatory Hypoferraemia.

Authors:  Andrew E Armitage; Pei Jin Lim; Joe N Frost; Sant-Rayn Pasricha; Elizabeth J Soilleux; Emma Evans; Alireza Morovat; Ana Santos; Rebeca Diaz; Daniel Biggs; Benjamin Davies; Uzi Gileadi; Peter A Robbins; Samira Lakhal-Littleton; Hal Drakesmith
Journal:  J Innate Immun       Date:  2016-07-16       Impact factor: 7.349

View more
  3 in total

1.  Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  Peter Santer; Anne McGahey; Matthew C Frise; Nayia Petousi; Nick P Talbot; Richard Baskerville; Mona Bafadhel; Annabel H Nickol; Peter A Robbins
Journal:  BMJ Open Respir Res       Date:  2020-06

2.  Iron supplementation inhibits hypoxia-induced mitochondrial damage and protects zebrafish liver cells from death.

Authors:  Ruiqin Hu; Genfang Li; Qianghua Xu; Liangbiao Chen
Journal:  Front Physiol       Date:  2022-08-26       Impact factor: 4.755

Review 3.  The Molecular Mechanisms of Iron Metabolism and Its Role in Cardiac Dysfunction and Cardioprotection.

Authors:  Tanya Ravingerová; Lucia Kindernay; Monika Barteková; Miroslav Ferko; Adriana Adameová; Vladislava Zohdi; Iveta Bernátová; Kristina Ferenczyová; Antigone Lazou
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.